Phaseline

Targets › SIGLEC10

SIGLEC10 (Sialic acid-binding Ig-like lectin 10): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- or alpha-2,6-linked sialic acid (By similarity). (UniProt, Q96LC7)

Open in Phaseline: the race on SIGLEC10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OncoC4ONC-841
Anti-SIGLEC10 antibody with IgG4 Fc domain
SIGLEC10Phase 1Advanced Solid TumorSep 2027

Conditions

Advanced Solid Tumor (1)

Modalities

antibody (1)

Companies

OncoC4 (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.